FDA alert on Xeljanz safety

26 February 2019

Following last week’s news from Pfizer (NYSE: PFE) that it would be transitioning patients on a 10mg dosage of Xeljanz (tofacitinib) to the 5mg strength due to safety concerns stemming from a post-marketing study, the US Food and Drug Administration (FDA) has issued a warning.

An increased risk of blood clots in the lungs, along with a greater danger of death, was found among rheumatoid arthritis (RA) patients taking the stronger dosage of the US pharma major’s drug.

The FDA has stressed in its warning that it has not approved the 10mg twice daily dose for RA, but rather that this strength is only approved in the dosing regimen for patients with ulcerative colitis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK